News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RevMedx Release: FDA Clears XSTAT For The Treatment Of Severe Bleeding From Gunshot And Stab Wounds In Arms Or Legs.



8/22/2017 7:54:49 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

WILSONVILLE, Ore., Aug. 22, 2017 /PRNewswire-iReach/ -- RevMedx, Inc. announced today that the FDA has cleared the XSTAT 12 and XSTAT 30 hemostatic devices for the control of severe, life-threatening bleeding from narrow entrance extremity wounds.  Previously limited to treating junctional wounds in the groin or shoulder area, XSTAT devices can now be used to treat severe bleeding from bullet or knife wounds located in an arm or leg.   

XSTAT 12 and 30 work by injecting a group of small, rapidly-expanding sponges into a wound cavity using a syringe-like applicator. In a wound, the sponges rapidly expand and exert hemostatic pressure. Unlike traditional methods that may take several minutes to be effective, XSTAT can stop bleeding in seconds to stabilize injuries until patients reach an emergency facility.  The XSTAT 12's smaller applicator, approximately 12 mm in diameter, enables treatment of narrow-entrance wounds from small caliber ammunition and stabbings.  Since its launch in 2014, there have been numerous successful uses of XSTAT devices in civilian and military pre-hospital settings. 

"We are pleased with the FDA's decision to add extremity wounds to XSTAT's marketing clearance," says Andrew Barofsky, RevMedx's CEO. "Our mission is to reduce death and disability from traumatic bleeding injuries caused by war, violence or accidents.  The expansion of XSTAT's indications accelerates fulfillment of this mission by providing first responders with an additional capability to treat penetrating injuries located in an arm, leg, shoulder or groin."

Early control of severe bleeding may prevent shock and may be life-saving.  The United States Army Institute of Surgical Research reports that 30 to 40 percent of civilian deaths by traumatic injury are the result of hemorrhaging; of those deaths, 33 to 56 percent occur before the patient reaches an emergency care facility.

About RevMedx

Based in Wilsonville, Oregon, RevMedx is a privately held medical device company whose goal is to design, develop, and manufacture innovative medical products that save lives. Our product line includes XSTAT, XGAUZE, AIRWRAP, PARABELT, SHARKBITE Blast Injury Kits, and TX Series Ratcheting Tourniquets.  Additional information about RevMedx and our products can be found at www.revmedx.com.

Media Contact:Will Fox, RevMedx, Inc., 503-504-2642, will.fox@revmedx.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RevMedx, Inc.


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES